FDA Approves Wegovy Pill: First Oral GLP-1 for Weight Loss

The FDA approved once-daily Wegovy tablets (semaglutide 25mg) in December 2026, making it the first oral GLP-1 medication approved for chronic weight management in the United States. This approval gives patients an alternative to weekly injections while delivering similar weight loss results.

What This Approval Means

Wegovy has been available as a weekly injection since 2021. The new tablet formulation uses the same active ingredient—semaglutide—but requires daily dosing instead of weekly injections. The FDA's approval was based on the OASIS 4 clinical trial, which compared oral semaglutide to placebo in adults with obesity or overweight plus weight-related health conditions.

This is the first oral GLP-1 medication approved specifically for weight management in the US. Rybelsus (oral semaglutide at lower doses) has been available for type 2 diabetes since 2019, but wasn't approved for weight loss.

OASIS 4 Trial Results

The approval was based on a 64-week phase 3 trial involving 307 adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related health condition. Participants with diabetes were excluded from this trial.

Weight Loss Outcomes

The trial also measured results regardless of whether participants stayed on treatment—a more conservative analysis that accounts for dropouts. In this analysis, average weight loss was 13.7% for oral Wegovy versus 2.3% for placebo.

Who Achieved Significant Weight Loss

• 76% of oral Wegovy participants lost at least 5% of their body weight, compared to 31% in the placebo group
• 5% weight loss is generally considered clinically meaningful—enough to improve weight-related health markers like blood pressure and cholesterol

How It Compares to Injectable Wegovy

Novo Nordisk described the oral version as having "similar efficacy" to the injectable formulation. The STEP 1 trial of injectable Wegovy (2.4mg weekly) showed 14.9% average weight loss at 68 weeks—comparable to the oral version's 17.4% result in OASIS 4.

Direct head-to-head comparison trials haven't been published yet. The similar outcomes in separate trials suggest the delivery method may not significantly impact efficacy, though trial populations and designs differed.

Dosing and Administration

Oral Wegovy tablets must be taken once daily on an empty stomach, at least 30 minutes before eating, drinking, or taking other medications. This timing requirement exists because stomach acid can degrade semaglutide—the tablets include absorption enhancers to help the medication survive the digestive process.

Titration Schedule

Like injectable Wegovy, the oral version requires gradual dose escalation to minimize gastrointestinal side effects. The FDA-approved schedule hasn't been publicly detailed yet, but the starting dose will be 1.5mg daily, escalating to a maintenance dose of 25mg daily over several months.

Side Effects Profile

The OASIS 4 trial reported side effects consistent with other GLP-1 medications. Gastrointestinal effects were most common.

Most Common Side Effects

• Nausea — Most frequently reported, especially during dose escalation
• Diarrhea — Common, typically improves over time
• Vomiting — Occurred in a notable portion of participants

Serious Risks

Oral Wegovy carries the same boxed warning as injectable Wegovy about potential thyroid tumors, based on rodent studies. The medication is contraindicated in people with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Other serious risks include pancreatitis, gallbladder disease, kidney problems, and severe allergic reactions—consistent with the injectable formulation.

Who It's Approved For

The FDA approved oral Wegovy for two indications:

• Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition like hypertension, type 2 diabetes, or high cholesterol
• Reducing cardiovascular risk (death, heart attack, stroke) in adults with established cardiovascular disease and either obesity or overweight

The approval does not cover patients under 18 years old. The medication is contraindicated in anyone with personal or family history of medullary thyroid carcinoma or MEN 2.

Availability and Pricing

Novo Nordisk announced the starting dose (1.5mg tablets) will launch in early January 2026. The company stated a list price of $149 per month with savings offers, though this likely applies to the starting dose rather than the full maintenance dose.

For context, injectable Wegovy has a list price exceeding $1,300 monthly without insurance. The lower announced price for oral Wegovy could improve access, though we don't yet know the price for higher maintenance doses or how insurance coverage will work.

Don't Want to Wait Until January 2026?

If you're interested in GLP-1 medication now rather than waiting for oral Wegovy's launch, compounded semaglutide is available today through telehealth providers.

What We Don't Know Yet

Several questions remain about oral Wegovy:

• Insurance coverage: Will plans that cover injectable Wegovy also cover the oral version? Will prior authorization requirements differ?
• Long-term adherence: Will daily dosing with fasting requirements be easier or harder than weekly injections?
• Full pricing structure: What will maintenance doses cost beyond the $149 starting price?
• Real-world effectiveness: The strict dosing requirements (empty stomach, 30-minute wait) may affect how well the medication works outside clinical trials where adherence is closely monitored.

Practical Implications

This approval expands options for people who want GLP-1 medication for weight management but prefer not to inject. Whether oral versus injectable is better depends on individual preferences:

Oral Wegovy May Appeal If You:

• Prefer not to inject or have needle aversion
• Have a consistent morning routine where fasting 30 minutes is manageable
• Want to avoid injection site reactions
• Find daily medication routines easier to remember than weekly

Injectable Wegovy May Appeal If You:

• Prefer once-weekly dosing to daily pills
• Have an irregular schedule that makes fasting windows difficult
• Don't mind injections (which many people find easier than expected)
• Want the established track record of the injectable formulation

Bottom Line

The FDA approval of oral Wegovy provides a legitimate alternative to injections for GLP-1-based weight management. The OASIS 4 trial showed weight loss comparable to injectable semaglutide, with a similar side effect profile.

Whether this formulation is better for any individual depends on personal preferences, lifestyle factors, insurance coverage, and how well you tolerate the medication. The strict dosing requirements (empty stomach, 30-minute fasting window) may be a non-issue for some and a dealbreaker for others.

If you're considering GLP-1 medication for weight management, talk to your doctor about whether oral or injectable formulations make more sense for your situation.

Related Resources